Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by longrun86on Sep 23, 2022 1:15pm
156 Views
Post# 34982388

RE:RE:RE:RE:Revenue comparison 10 years later

RE:RE:RE:RE:Revenue comparison 10 years laterThe shelf prospectus provides for optionality and I see it being wise to keep it going.

Management and the Board are likely averse to raising equity at these prices but the debt possibility of the shelf prospectus is interesting given that the financial assets of Knight will start rolling over and could be used to repay in addition to cash flow from operations.

Based on the last call, it is obvious Management is working on some significant opportunities and it is only a matter of time before we start to see some announcements. The equity and debt markets are tightening up and Knight is well positioned to be doing some deals in this environment.
<< Previous
Bullboard Posts
Next >>